230.01
price up icon6.25%   13.52
after-market After Hours: 229.99 -0.02 -0.01%
loading
Abbvie Inc stock is traded at $230.01, with a volume of 9.70M. It is up +6.25% in the last 24 hours and up +6.63% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$216.49
Open:
$221.94
24h Volume:
9.70M
Relative Volume:
1.50
Market Cap:
$406.38B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
113.45
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+3.80%
1M Performance:
+6.63%
6M Performance:
+0.92%
1Y Performance:
+24.13%
1-Day Range:
Value
$221.94
$232.32
1-Week Range:
Value
$215.37
$232.32
52-Week Range:
Value
$181.73
$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
57,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2026-07-30
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV vs LLY, JNJ, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABBV icon
ABBV
Abbvie Inc
230.01 382.49B 62.82B 3.60B 19.98B 2.0274
LLY icon
LLY
Lilly Eli Co
1,102.08 979.64B 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
231.29 549.78B 96.36B 21.04B 17.80B 8.6488
MRK icon
MRK
Merck Co Inc
115.48 281.24B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
148.93 280.64B 54.66B 13.58B 16.05B 7.0171

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-30-26 Upgrade BofA Securities Neutral → Buy
Apr-21-26 Initiated Canaccord Genuity Buy
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-08-26 Downgrade Wolfe Research Outperform → Peer Perform
Jan-07-26 Resumed UBS Neutral
Dec-10-25 Upgrade HSBC Securities Hold → Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-04-25 Downgrade DZ Bank Buy → Hold
Oct-14-25 Downgrade Erste Group Buy → Hold
Oct-01-25 Downgrade HSBC Securities Buy → Hold
Sep-17-25 Upgrade Berenberg Hold → Buy
Aug-12-25 Resumed Piper Sandler Overweight
Aug-07-25 Upgrade Daiwa Securities Neutral → Outperform
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
Jun 22, 2026

Why AbbVie Stock Jumped Today - The Globe and Mail

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio - Investing News Network

Jun 22, 2026
pulisher
Jun 22, 2026

Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma

Jun 22, 2026
pulisher
Jun 22, 2026

Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger - Insider Monkey

Jun 22, 2026
pulisher
Jun 22, 2026

Can Zumilokibart Become the Next Megablockbuster? Inside AbbVie’s $10.9 Billion Bet on Apogee - NAI500

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie's Immunology Dominance Contributes to Its Wide Economic Moat - Morningstar

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie M&A, FDA reversals, a CAR T first — a BioCentury podcast - biocentury.com

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie seeks further extension to immunology franchise via $10.9B Apogee deal - biocentury.com

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? - Yahoo Finance

Jun 22, 2026
pulisher
Jun 22, 2026

ABBV: $10.9B acquisition adds innovative immunology assets, targeting blockbuster growth by 2032 - TradingView

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? - The Motley Fool

Jun 22, 2026
pulisher
Jun 22, 2026

Parkinson’s Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail - Barchart.com

Jun 22, 2026
pulisher
Jun 22, 2026

Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer - The Globe and Mail

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie Inc.’s Stock Price Soars to $230.01, Marking a Stellar 6.25% Increase - Smartkarma

Jun 22, 2026
pulisher
Jun 22, 2026

Stocks to Watch Recap: SpaceX, Alphabet, AbbVie, Intel - WSJ

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie Inc (ABBV) Shares Surge 6.2% -- What GF Score of 82 Tells Investors - GuruFocus

Jun 22, 2026
pulisher
Jun 22, 2026

The $11 Billion Reason Abbvie Stock Is Up Today - Barchart.com

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie (ABBV) Acquires Apogee Therapeutics for $10.9 Billion - GuruFocus

Jun 22, 2026
pulisher
Jun 22, 2026

Apogee: "Hold" On AbbVie $10.9B Buyout And Extended Half-Life IL-13 Zumilokibart For AD - Seeking Alpha

Jun 22, 2026
pulisher
Jun 22, 2026

Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising - Barron's

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie: Why The Pharma Wins Twice With Its Apogee Acquisition (NASDAQ:APGE) - Seeking Alpha

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie (ABBV) Jumps 6.2% to $229.97 - AlphaStreet

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma S - GuruFocus

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie seals $10.9 billion deal to acquire biotech Apogee Therapeutics - The Business Journals

Jun 22, 2026
pulisher
Jun 22, 2026

Take care of migraines with headache-free advice from AbbVie - WSBT

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie Up Nearly 7%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk - Moomoo

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie up 7% amid Apogee Therapeutics $10.9B deal - Breakingthenews.net

Jun 22, 2026
pulisher
Jun 22, 2026

Truist reiterates Kymera stock Buy rating after AbbVie deal - Investing.com

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers - marketscreener.com

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion - Yahoo Finance

Jun 22, 2026
pulisher
Jun 22, 2026

Truist reiterates Kymera stock Buy rating after AbbVie deal By Investing.com - Investing.com Canada

Jun 22, 2026
pulisher
Jun 22, 2026

ABBV: Acquisition adds high-value immunology assets with blockbuster potential and long-term growth prospects - TradingView

Jun 22, 2026
pulisher
Jun 22, 2026

Crude Oil Falls Over 2%; Getty Images Shares Spike Higher - Benzinga

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie gains as investors weigh stronger growth outlook and recent pipeline wins - Quiver Quantitative

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie sharpens immunology focus with $10.9 billion Apogee deal By Reuters - Investing.com

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie Inc. (ABBV) Announces Acquisition of Apogee Therapeutics - GuruFocus

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie sharpens immunology focus with $10.9 billion Apogee deal - Reuters

Jun 22, 2026
pulisher
Jun 22, 2026

ABBV Acquires Apogee Therapeutics for $10.9 Billion to Boost Imm - GuruFocus

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Expand Immunology Pipeline - GuruFocus

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie acquires Apogee Therapeutics in $10.9B deal - grafa.com

Jun 22, 2026
pulisher
Jun 22, 2026

ABBV: Acquisition adds high-value immunology assets with blockbuster potential and early 2030 launch - TradingView

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie deepens immunology legacy in $10.9bn Apogee buyout - Pharmaceutical Technology

Jun 22, 2026
pulisher
Jun 22, 2026

Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover - TechStock²

Jun 22, 2026
pulisher
Jun 22, 2026

RCSIntnl. BiotechnologyPortfolio company Apogee to be acquired by AbbVie - TradingView

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal - The Boston Globe

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie on Pace for Largest Percent Increase Since October 2025 -- Data Talk - Moomoo

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie (ABBV) Set to Acquire Apogee Therapeutics (APGE) for $11 Billion - GuruFocus

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal - marketscreener.com

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead? - Yahoo Finance

Jun 22, 2026
pulisher
Jun 22, 2026

As AbbVie eyes Apogee, these biotech stocks earn the highest quant ratings - MSN

Jun 22, 2026
pulisher
Jun 22, 2026

AbbVie Inc Stock (ABBV) Opened Up by 3.26% on Jun 22: Key Drivers Unveiled - TradingKey

Jun 22, 2026

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
MRK MRK
$115.48
price up icon 1.41%
NVS NVS
$148.93
price up icon 1.26%
AZN AZN
$176.43
price up icon 0.86%
JNJ JNJ
$231.29
price up icon 1.27%
NVO NVO
$45.88
price up icon 6.23%
Cap:     |  Volume (24h):